The experts in Intrinsically Disordered Protein Drug Discovery

Drug design technology suitable for every protein target and molecular class.

Unique Selling Propositions

NMR-AI drug screening

We leverage proprietary nuclear magnetic resonance (NMR) experiments at every stage of drug discovery, which are bolstered by our artificial intelligence (AI) and cheminformatics tools. These tools utilize 1D NMR screening data to boost AI-driven drug design and accelerate 3D structure calculations with our ML-based 4D NMR method. We can screen ~1500 compounds/day for binding to all kinds of proteins, including intrinsically disordered proteins (IDPs) and transmembrane proteins.

AI|ffinity services

About us

AI|ffinity, founded in late 2021 as a spin-off from Masaryk University and supported by the Central European Institute of Technology (CEITEC), is a company specializing in creating innovative solutions for the pharmaceutical and biotechnology industries. By harnessing the power of NMR, AI, and Cheminformatics, AI|ffinity focuses on quantifying protein-ligand binding affinity for hit discovery and lead optimization, characterizing protein-ligand interactions, and determining protein 3D structures.

Operating from its headquarters in Brno (NMR hub), Czech Republic, with additional facilities in Prague (CADD hub), AI|ffinity aims to expedite the initial phases of drug discovery, improve success rates, and reduce costs by eliminating unnecessary experiments. Its comprehensive NMR-AI platform covers the entire target-to-lead process, while its 4D NMR-AI technology finds applications in drug design and protein engineering.

Let's work together to conquer previously undruggable targets

Thomas Evangelidis CEO/CTO AI|ffinity

We welcome partnerships with biotech and pharma companies, as well as leading academic institutions, to co-develop new drugs, antibodies, engineered proteins, and software solutions.

Partner with AI|ffinity now

Funded by